Peptides

Abstract

Provided is a peptide compound comprising the amino acid sequence: Xaa1-Lys-Xaa3-Ser-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13 wherein: Xaa1 represents Ala or Ser, or is absent, wherein the N-terminal amino acid optionally includes an N-terminal 3,4-dihydrocinnamic acid group; Xaa5 represents Tyr, DOPA or a single bond; Xaa3 and Xaa6 independently represent Pro, Hyp or diHyp; Xaa7, Xaa8, Xaa9, Xaa10, and Xaa11 are each optional (in which case Xaa6 is bonded to Xaa12), and are independently selected from the group Pro, Hyp, diHyp, Thr, DOPA and Tyr; Xaa12 represents Pro, Hyp, diHyp, Thr, DOPA or Tyr; and Xaa13 represents Lys or is absent, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide compound, provided that when the N-terminal 3,4-dihydrocinnamic acid group is not present, Xaa1 represents Ala or is absent and Xaa13 represents Lys, then Xaa12 represents Pro, Hyp, diHyp or Thr. The compounds are particularly useful in for treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as anorectal diseases, inflammatory bowel diseases, gynaecological diseases and dental diseases.

Dependencies are inferred from the claim text.